150 related articles for article (PubMed ID: 38423047)
21. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
Altorki NK; McGraw TE; Borczuk AC; Saxena A; Port JL; Stiles BM; Lee BE; Sanfilippo NJ; Scheff RJ; Pua BB; Gruden JF; Christos PJ; Spinelli C; Gakuria J; Uppal M; Binder B; Elemento O; Ballman KV; Formenti SC
Lancet Oncol; 2021 Jun; 22(6):824-835. PubMed ID: 34015311
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial.
Palma DA; Bahig H; Hope A; Harrow S; Debenham BJ; Louie AV; Vu TTTT; Filion E; Bezjak A; Campeau MP; Duimering A; Giuliani ME; Laba JM; Lang P; Lok BH; Qu XM; Raman S; Rodrigues GB; Goodman CD; Gaede S; Morisset J; Warner A; Dhaliwal I; Ryerson CJ
JAMA Oncol; 2024 May; 10(5):575-582. PubMed ID: 38451491
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P
BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805
[TBL] [Abstract][Full Text] [Related]
25. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
[TBL] [Abstract][Full Text] [Related]
26. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study.
Chalkidou A; Macmillan T; Grzeda MT; Peacock J; Summers J; Eddy S; Coker B; Patrick H; Powell H; Berry L; Webster G; Ostler P; Dickinson PD; Hatton MQ; Henry A; Keevil S; Hawkins MA; Slevin N; van As N
Lancet Oncol; 2021 Jan; 22(1):98-106. PubMed ID: 33387498
[TBL] [Abstract][Full Text] [Related]
28. Dose-effect Relationship of Kidney Function After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: Trog 15.03 Fastrack Ii.
Gaudreault M; Hardcastle N; Jackson P; McIntosh L; Higgs B; Pryor D; Sidhom M; Dykyj R; Moore A; Kron T; Siva S
Int J Radiat Oncol Biol Phys; 2024 Apr; ():. PubMed ID: 38679212
[TBL] [Abstract][Full Text] [Related]
29. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship.
Siva S; Jackson P; Kron T; Bressel M; Lau E; Hofman M; Shaw M; Chander S; Pham D; Lawrentschuk N; Wong LM; Goad J; Foroudi F
Radiother Oncol; 2016 Mar; 118(3):540-6. PubMed ID: 26873790
[TBL] [Abstract][Full Text] [Related]
30. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma.
Reynolds HM; Parameswaran BK; Finnegan ME; Roettger D; Lau E; Kron T; Shaw M; Chander S; Siva S
PLoS One; 2018; 13(8):e0202387. PubMed ID: 30114235
[TBL] [Abstract][Full Text] [Related]
31. Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial.
Palma DA; Chen H; Bahig H; Gaede S; Harrow S; Laba JM; Qu XM; Rodrigues GB; Yaremko BP; Yu E; Louie AV; Dhaliwal I; Ryerson CJ
BMC Cancer; 2019 Dec; 19(1):1206. PubMed ID: 31829203
[TBL] [Abstract][Full Text] [Related]
32. Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer.
Ali M; Koo K; Chang D; Chan P; Oon SF; Moon D; Murphy DG; Eapen R; Goad J; Lawrentschuk N; Azad AA; Chander S; Shaw M; Hardcastle N; Siva S
Radiat Oncol; 2024 Feb; 19(1):23. PubMed ID: 38355495
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma in Non-surgical Candidates: Initial Clinical Experience.
Chang JH; Cheung P; Erler D; Sonier M; Korol R; Chu W
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e109-14. PubMed ID: 27131756
[TBL] [Abstract][Full Text] [Related]
34. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
Siva S; Bressel M; Mai T; Le H; Vinod S; de Silva H; Macdonald S; Skala M; Hardcastle N; Rezo A; Pryor D; Gill S; Higgs B; Wagenfuehr K; Montgomery R; Awad R; Chesson B; Eade T; Wong W; Sasso G; De Abreu Lourenco R; Kron T; Ball D; Neeson P;
JAMA Oncol; 2021 Oct; 7(10):1476-1485. PubMed ID: 34455431
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK.
Correa RJM; Louie AV; Staehler M; Warner A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Siva S
J Urol; 2019 Jun; 201(6):1097-1104. PubMed ID: 30741849
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations.
Correa RJM; Rodrigues GB; Chen H; Warner A; Ahmad B; Louie AV
Am J Clin Oncol; 2018 Jun; 41(6):568-575. PubMed ID: 27635623
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial.
Taniguchi CM; Frakes JM; Aguilera TA; Palta M; Czito B; Bhutani MS; Colbert LE; Abi Jaoude J; Bernard V; Pant S; Tzeng CD; Kim DW; Malafa M; Costello J; Mathew G; Rebueno N; Koay EJ; Das P; Ludmir EB; Katz MHG; Wolff RA; Beddar S; Sawakuchi GO; Moningi S; Slack Tidwell RS; Yuan Y; Thall PF; Beardsley RA; Holmlund J; Herman JM; Hoffe SE
Lancet Oncol; 2023 Dec; 24(12):1387-1398. PubMed ID: 38039992
[TBL] [Abstract][Full Text] [Related]
40. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
